Education
About Us
Working with TipRanks
Follow Us
Restart Life Sciences Corp. (TSE:HEAL)
:HEAL
HEAL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.20
Previous CloseN/A
Volume800.00
Average Volume (3M)30.44K
Market Cap
C$1.99M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)60.00K
Price to Earnings (P/E)4.0
Beta2.47
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,230,354
10 Day Avg. Volume37,199
30 Day Avg. Volume30,440
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Restart Life Sciences News
PremiumCompany Announcements
Nova Mentis Announces Share Consolidation and Name ChangePremiumCompany Announcements
Nova Mentis Appoints New CEO to Drive Growth
PremiumCompany Announcements
Nova Mentis Life Science Announces Strategic IP Deal
PremiumCompany Announcements
Nova Mentis Welcomes New Board MemberOptions Prices
Currently, No data available
---
Ownership Overview
15.35% Insiders
―
Mutual Funds
― Other Institutional Investors
84.65% Public Companies and
Individual Investors
HEAL FAQ
What was Restart Life Sciences Corp.’s price range in the past 12 months?
Restart Life Sciences Corp. lowest stock price was C$0.03 and its highest was C$0.20 in the past 12 months.
What is Restart Life Sciences Corp.’s market cap?
Restart Life Sciences Corp.’s market cap is C$1.99M.
When is Restart Life Sciences Corp.’s upcoming earnings report date?
Restart Life Sciences Corp.’s upcoming earnings report date is Aug 22, 2025 which is in 87 days.
How were Restart Life Sciences Corp.’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences Corp. overvalued?
According to Wall Street analysts Restart Life Sciences Corp.’s price is currently Overvalued.
Does Restart Life Sciences Corp. pay dividends?
Restart Life Sciences Corp. does not currently pay dividends.
What is Restart Life Sciences Corp.’s EPS estimate?
Restart Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences Corp. have?
Restart Life Sciences Corp. has 33,230,354 shares outstanding.
What happened to Restart Life Sciences Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:HEAL
Company Description
Restart Life Sciences Corp.
Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
Technical Analysis
Cybin
―
Braxia Scientific
―
Entheon Biomedical
―
Doseology Sciences
―
GeneTether Therapeutics, Inc.
―